目的 研究通心絡膠囊聯(lián)合阿加曲班注射液治療輕中度急性腦梗死的臨床療效。方法 選取2017年3月-2019年9月在天津市濱海新區(qū)大港醫(yī)院治療的80例輕中度急性腦梗死患者，隨機分為對照組和治療組，每組各40例。對照組靜脈滴注阿加曲班注射液，60 mg加入生理鹽水250 mL中靜滴24 h，持續(xù)2 d，第3天開始劑量調整為60 mg加到生理鹽水100 mL，靜滴3 h，2次/d，持續(xù)5 d。治療組在對照組的基礎上口服通心絡膠囊，4粒/次，3次/d，連續(xù)治療14 d。觀察兩組患者臨床療效，同時比較治療前后兩組患者血凝功能指標和美國國立衛(wèi)生研究院卒中量表（NIHSS）評分。結果 治療后，對照組和治療組臨床有效率分別為77.50%和95.00%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者凝血酶原時間（PT）、活化部分凝血活酶時間（APTT）水平明顯升高（P<0.05），而D-D二聚體（D-D）、纖維蛋白原（FIB）水平明顯降低（P<0.05），且治療組的血凝功能指標明顯好于對照組（P<0.05）。治療后，兩組NIHSS評分均顯著降低（P<0.05），且治療組評分明顯低于對照組（P<0.05）。結論 通心絡膠囊聯(lián)合阿加曲班注射液治療輕中度急性腦梗死有較明顯的臨床療效，具有一定的臨床推廣應用價值。

Objective To study the clinical effect of Tongxinluo Capules combined with Argatroban Injection in treatment of mild to moderate acute cerebral infarction. Methods Patients (80 cases) with moderate acute cerebral infarction in Dagang Hospital of Tianjin Binhai New Area from March 2017 to September 2019 were randomly divided into control and treatment groups, and each had 40 cases. Patients in the control group iv administered with Argatroban Injection, 60 mg added into normal saline 250 mL, and intravenous drip for 24 h for 2 d, the dose was adjusted to 60 mg added into normal saline 100 mL for 3 h from day 3, twice daily, and they were treated for 5 d. Patients in the treatment group were po administered with Tongxinluo Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the coagulation function indexes and NIHSS score in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 77.50% and 95.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the PT and APTT level in two groups was significantly increased (P<0.05), but the FIB and D-D level was significantly decreased (P<0.05), and the coagulation function indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the NIHSS score in two groups was significantly decreased (P<0.05), and the score in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Tongxinluo Capules combined with Argatroban Injection has obvious clinical effect in treatment of mild to moderate acute cerebral infarction, and which has a certain clinical application value.

R971